Back to Journals » Neuropsychiatric Disease and Treatment » Volume 13

Influence of fluvoxamine on plasma interleukin-6 or clinical improvement in patients with major depressive disorder

Authors Yoshimura R, Katsuki A, Atake K, Hori H, Igata R, Konishi Y

Received 24 September 2016

Accepted for publication 30 December 2016

Published 14 February 2017 Volume 2017:13 Pages 437—441

DOI https://doi.org/10.2147/NDT.S123121

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Lucy Goodman

Peer reviewer comments 2

Editor who approved publication: Dr Taro Kishi


Reiji Yoshimura, Asuka Katsuki, Kiyokazu Atake, Hikaru Hori, Ryohei Igata, Yuki Konishi

Department of Psychiatry, University of Occupational and Environmental Health, Yahatanishi-ku, Kitakyushu, Fukuoka, Japan


Objectives: The etiology of depression remains unknown. There is, however, a growing body of evidence that cytokines are involved in the pathophysiology of depression. The aim of this study is to investigate the effects of fluvoxamine on plasma interleukin-6 (IL-6) levels and on clinical improvement of the depressive state.
Subjects and methods: Thirty patients who met the DSM-IV criteria for major depressive disorder (MDD) were enrolled in the study. Thirteen were male and 17 were female, and their ages ranged from 26 to 70 years (mean ± standard deviation 45.0±14.2). The patients were treated with fluvoxamine for 8 weeks. The dosages of fluvoxamine varied among the patients and, based on ethical considerations, were not fixed.
Results: The fluvoxamine doses were positively related to plasma fluvoxamine levels (r=0.8798, P<0.001). A significant correlation was observed between the patients’ plasma IL-6 levels and their 17-item Hamilton Rating Scale for Depression (HAMD17) scores (r=0.4555, P=0.0010). A positive correlation was found between the delta plasma IL-6 (week 0–week 8) and the delta HAMD17 (week 0–week 8) (r=0.5226, P=0.002).
Conclusion: Effect of fluvoxamine on IL-6 is partially associated with its clinical efficacy for MDD.

Keywords: fluvoxamine, interleukin, Hamilton Rating Scale for Depression, major depressive disorder

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]